Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

Bone Marrow Transplantation volume 34, pages 161–167 (2004)Cite this article

Summary:

Autologous stem cell transplant (SCT) improves survival in multiple myeloma (MM) and remains the standard of care for eligible patients. Nearly a third of patients with newly diagnosed MM fail initial therapy aimed at reducing tumor burden preceding SCT (primary refractory). It is unclear if an initial response is important for successful SCT. We evaluated our experience with SCT in 50 patients with primary refractory MM and compared it to 101 patients with chemosensitive disease receiving SCT. The study cohort had a median age of 56 years (range 29–72) consisting of 87 males (58%). A total of 46 patients (92%) in the refractory group and 100 (99%) in the chemosensitive group had a response to transplant (50% or greater reduction in the M-protein). In all, 10 refractory patients (20%) and 35 (35%) in the chemosensitive group achieved a CR (P=0.06). The 1-year estimated progresion-free survival from the time of transplant for the refractory group was 70% compared to 83% for the chemosensitive group (P=0.65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bataille R, Harousseau JL . Multiple myeloma. New Engl J Med 1997; 336: 1657–1664.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.

    Article  PubMed  Google Scholar 

  3. Kyle RA . Long-term survival in multiple myeloma. New Engl J Med 1983; 308: 314–316.

    Article  CAS  PubMed  Google Scholar 

  4. Alexanian R, Bonnet J, Gehan E et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382–389.

    Article  CAS  PubMed  Google Scholar 

  5. Kyle R, Gertz M, Witzig T et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

    Article  PubMed  Google Scholar 

  6. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. [see comments.]. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  8. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7–11.

    CAS  Google Scholar 

  9. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  PubMed  Google Scholar 

  10. Attal M, Harousseau J, Facon T et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective Randomized Study of the “Intergroupe Francophone du Myelome” (IFM 94) [abstract]. Blood 2002; 100 Abstract # 7.

  11. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1851.

    Article  CAS  PubMed  Google Scholar 

  12. Stewart FM . Indications and relative indications for stem cell transplantation in non-Hodgkin's lymphoma. Leukemia 1993; 7: 1091–1094.

    CAS  PubMed  Google Scholar 

  13. Rajkumar SV, Fonseca R, Lacy MQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267–1272.

    Article  CAS  PubMed  Google Scholar 

  14. Alexanian R, Dimopoulos MA, Delasalle KB et al. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 118–121.

    PubMed  Google Scholar 

  15. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356.

    Article  CAS  PubMed  Google Scholar 

  16. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  17. Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387.

    CAS  PubMed  Google Scholar 

  18. Kaplan E, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  19. Cox D . Regression models and life tables. J R Stat Soc 1972; 34: 187–202.

    Google Scholar 

  20. McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.

    Article  CAS  PubMed  Google Scholar 

  21. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

    CAS  PubMed  Google Scholar 

  22. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  23. Blade J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845–849.

    Article  CAS  PubMed  Google Scholar 

  24. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE . Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol 1999; 16: 245–254.

    Article  CAS  PubMed  Google Scholar 

  25. Powles R, Sirohi B, Kulkarni S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone Marrow Transplant 2002; 30: 479–484.

    Article  CAS  PubMed  Google Scholar 

  26. Singhal S, Powles R, Sirohi B et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673–679.

    Article  CAS  PubMed  Google Scholar 

  27. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment* Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  28. Alexanian R, Weber D, Delasalle K et al. Value of intensive therapy supported by autologous stem cells (IT+ASCT) for primary resistant multiple myeloma. Blood 2002; 100 abstract: #672.

  29. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282.

    CAS  PubMed  Google Scholar 

  30. Blade J, Esteve J . Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843–847.

    Article  CAS  PubMed  Google Scholar 

  31. Dimopoulos MA, Hester J, Huh Y et al. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87: 730–734.

    Article  CAS  PubMed  Google Scholar 

  32. Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860–1866.

    CAS  PubMed  Google Scholar 

  33. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950–956.

    CAS  PubMed  Google Scholar 

  34. Schenkein DP, Koc Y, Alcindor T et al. Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor. Biol Blood Marrow Transplant 2000; 6: 448–455.

    Article  CAS  PubMed  Google Scholar 

  35. Rajkumar SV, Fonseca R, Lacy MQ et al. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant 1999; 23: 1261–1266.

    Article  CAS  PubMed  Google Scholar 

  36. Gertz MA, Witzig TE, Pineda AA et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19: 337–342.

    Article  CAS  PubMed  Google Scholar 

  37. Rajkumar SV, Fonseca R, Dispenzieri A et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979–983.

    Article  CAS  PubMed  Google Scholar 

  38. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on autologous transplantation in multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 132–139.

    PubMed  Google Scholar 

  39. Shimoni A, Smith TL, Aleman A et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001; 27: 821–828.

    Article  CAS  PubMed  Google Scholar 

  40. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838–847.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Hematological Malignancies Fund, Mayo Clinic and CA62242 from the National Cancer Institute.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN, USA

    S Kumar, M Q Lacy, A Dispenzieri, S V Rajkumar, R Fonseca, T E Witzig, J A Lust, P R Greipp, R A Kyle, M R Litzow & M A Gertz

  2. Department of Biostatistics, Mayo Clinic and Foundation, Rochester, MN, USA

    S Geyer & C Allmer

Authors
  1. S Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S V Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Geyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Allmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T E Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J A Lust
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P R Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R A Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M R Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Gertz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, S., Lacy, M., Dispenzieri, A. et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 34, 161–167 (2004). https://doi.org/10.1038/sj.bmt.1704545

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704545

Keywords

This article is cited by

Search

Advanced search

Quick links